HRT Financial’s Edgewise Therapeutics EWTX Stock Holding History

HRT Financial’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.45M	Buy	+85,000	New	+$2.93M	0.01%	1374

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HRT Financial's EWTX Position: Q4 2025 in Review

HRT Financial sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 52,203 shares — an estimated $846K sold.

HRT Financial first reported a position in EWTX in Q4 2023 and held it in 4 quarters. The position peaked at $2.57M in Q3 2024. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

HRT Financial reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 52,203 Edgewise Therapeutics shares in Q4 2025, an estimated $846K.
HRT Financial first reported a position in Edgewise Therapeutics in Q4 2023 and held it in 4 quarters.
HRT Financial's Edgewise Therapeutics position peaked at $2.57M in Q3 2024.
199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.